Journal of Clinical Endocrinology & Metabolism, Vol 76, 559-565, Copyright © 1993 by Endocrine Society

ARTICLES

Increased de novo hepatic lipogenesis in human immunodeficiency virus infection

MK Hellerstein, C Grunfeld, K Wu, M Christiansen, S Kaempfer, C Kletke and CH Shackleton
Department of Nutritional Sciences, University of California, Berkeley 94720.

We measured de novo lipogenesis in human immunodeficiency virus (HIV) infected men using a newly developed stable isotope method. HIV- infected subjects with a history of weight loss (n = 17, mean weight loss 14.9 +/- 3.2 kg), asymptomatic HIV-seropositive subjects with normal CD4 T-cell counts (n = 7) and healthy HIV seronegative controls (n = 11) were studied. Hepatic lipogenesis was determined by infusion of [2-13C]-acetate, using the recently described xenobiotic probe technique with mass isotopomer analysis. Hepatic acetyl-coenzyme A enrichment was measured by high performance liquid chromatography/mass spectrometry of secreted sulfamethoxazole-acetate, with measurement of incorporation into very low density lipoprotein-fatty acids by gas chromatography-mass spectrometry. Circulating tumor necrosis factor (TNF), interleukin-1 (IL-1), interferon alpha (IFN alpha), insulin, and triglycerides were measured concurrently, and 7-day weighed food records were performed. De novo hepatic lipogenesis was increased 3- to 4-fold in HIV-infected subjects with weight loss compared to normal controls (P < 0.05 for palmitate and stearate in both overnight-fasted and fed states), and was also significantly increased in asymptomatic HIV seropositive subjects. Circulating TNF and IL-1 were not measurable in any subject (detection limit 2 pg/ml for IL-1 and 20 pg/ml for TNF). Serum IFN alpha was measurable in 11 out of 17 subjects with wasting and correlated significantly with de novo lipogenesis in overnight- fasted but not fed states. Serum IFN alpha was unmeasurable in asymptomatic HIV-infected subjects despite elevated lipogenic rates. Serum triglyceride concentrations were elevated in subjects with weight loss (2.09 +/- 0.28 mmol/L) and asymptomatic HIV-positives (1.34 +/- 0.34 mmol/L) in comparison to controls (0.67 +/- 0.08 mmol/L), and correlated with lipogenesis. Food intake correlated inversely with lipogenesis in the overnight-fasted state. We conclude that HIV infection is characterized by abnormal fat anabolism. This applies to subjects with reduced lean body mass and to asymptomatic HIV-positive subjects with normal T-cell counts. The former observation may have implications for the pathophysiology and treatment of the wasting syndrome. The latter observation is consistent with activation of the immune response and a state of viral nonlatency in early HIV disease.

This article has been cited by other articles:

				M. N Woods, C. A Wanke, P.-R. Ling, K. M Hendricks, A. M Tang, T. A Knox, C. E Andersson, K. R Dong, S. C Skinner, and B. R Bistrian Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV Am. J. Clinical Nutrition, December 1, 2009; 90(6): 1566 - 1578. [Abstract] [Full Text] [PDF]

				M. N Woods, C. A Wanke, P.-R. Ling, K. M Hendricks, A. M Tang, C. E Andersson, K. R Dong, H. M. Sheehan, and B. R Bistrian Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus Am. J. Clinical Nutrition, April 1, 2009; 89(4): 1180 - 1187. [Abstract] [Full Text] [PDF]

				S. K. Grinspoon, C. Grunfeld, D. P. Kotler, J. S. Currier, J. D. Lundgren, M. P. Dube, S. E. Lipshultz, P. Y. Hsue, K. Squires, M. Schambelan, et al. State of the Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS: Executive Summary Circulation, July 8, 2008; 118(2): 198 - 210. [Full Text] [PDF]

				C. Grunfeld, D. P. Kotler, D. K. Arnett, J. M. Falutz, S. M. Haffner, P. Hruz, H. Masur, J. B. Meigs, K. Mulligan, P. Reiss, et al. Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors Circulation, July 8, 2008; 118(2): e20 - e28. [Full Text] [PDF]

				K. Samaras Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection J. Antimicrob. Chemother., February 1, 2008; 61(2): 238 - 245. [Abstract] [Full Text] [PDF]

				S. Johnsen, S. E. Dolan, K. V. Fitch, J. R. Kanter, L. C. Hemphill, J. M. Connelly, R. S. Lees, H. Lee, and S. Grinspoon Carotid Intimal Medial Thickness in Human Immunodeficiency Virus-Infected Women: Effects of Protease Inhibitor Use, Cardiac Risk Factors, and the Metabolic Syndrome J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4916 - 4924. [Abstract] [Full Text] [PDF]

				E. J. Parks and M. K. Hellerstein Thematic review series: Patient-Oriented Research. Recent advances in liver triacylglycerol and fatty acid metabolism using stable isotope labeling techniques J. Lipid Res., August 1, 2006; 47(8): 1651 - 1660. [Abstract] [Full Text] [PDF]

				D. N. Reeds, K. E. Yarasheski, L. Fontana, W. T. Cade, E. Laciny, A. DeMoss, B. W. Patterson, W. G. Powderly, and S. Klein Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E47 - E53. [Abstract] [Full Text] [PDF]

				S. Grinspoon and A. Carr Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults N. Engl. J. Med., January 6, 2005; 352(1): 48 - 62. [Full Text] [PDF]

				P. Crenn, B. Rakotoanbinina, J.-J. Raynaud, F. Thuillier, B. Messing, and J.-C. Melchior Hyperphagia Contributes to the Normal Body Composition and Protein-Energy Balance in HIV-Infected Asymptomatic Men J. Nutr., September 1, 2004; 134(9): 2301 - 2306. [Abstract] [Full Text] [PDF]

				K. E. Yarasheski, P. Tebas, S. Claxton, D. Marin, T. Coleman, W. G. Powderly, and C. F. Semenkovich Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E899 - E905. [Abstract] [Full Text] [PDF]

				D. N. Reeds, B. Mittendorfer, B. W. Patterson, W. G. Powderly, K. E. Yarasheski, and S. Klein Alterations in lipid kinetics in men with HIV-dyslipidemia Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E490 - E497. [Abstract] [Full Text] [PDF]

				F. Jahoor, S. Abramson, and W. C Heird The protein metabolic response to HIV infection in young children Am. J. Clinical Nutrition, July 1, 2003; 78(1): 182 - 189. [Abstract] [Full Text] [PDF]

				J.-M. Schwarz, P. Linfoot, D. Dare, and K. Aghajanian Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets Am. J. Clinical Nutrition, January 1, 2003; 77(1): 43 - 50. [Abstract] [Full Text] [PDF]

				R. V. Sekhar, F. Jahoor, A. C. White, H. J. Pownall, F. Visnegarwala, M. C. Rodriguez-Barradas, M. Sharma, P. J. Reeds, and A. Balasubramanyam Metabolic basis of HIV-lipodystrophy syndrome Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E332 - E337. [Abstract] [Full Text] [PDF]

				M. Shahmanesh, H. Jaleel, Y. DeSilva, J. D C Ross, M. Caslake, and R. Cramb Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype Sex Transm Inf, August 1, 2001; 77(4): 283 - 286. [Abstract] [Full Text] [PDF]

				T. L. Miller, B. E. Mawn, E. J. Orav, D. Wilk, G. A. Weinberg, J. Nicchitta, L. Furuta, R. Cutroni, K. McIntosh, S. K. Burchett, et al. The Effect of Protease Inhibitor Therapy on Growth and Body Composition in Human Immunodeficiency Virus Type 1-Infected Children Pediatrics, May 1, 2001; 107(5): 77e - 77. [Abstract] [Full Text]

				S. Q Siler, R. A Neese, and M. K Hellerstein De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption Am. J. Clinical Nutrition, November 1, 1999; 70(5): 928 - 936. [Abstract] [Full Text] [PDF]

				K. Mulligan, V. W. Tai, and M. Schambelan Use of Growth Hormone and Other Anabolic Agents in AIDS Wasting JPEN J Parenter Enteral Nutr, November 1, 1999; 23(6_suppl): S202 - S209. [Abstract] [PDF]

				C. Corcoran and S. Grinspoon Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., June 3, 1999; 340(22): 1740 - 1750. [Full Text] [PDF]

				C. Hadigan, K. Miller, C. Corcoran, E. Anderson, N. Basgoz, and S. Grinspoon Fasting Hyperinsulinemia and Changes in Regional Body Composition in Human Immunodeficiency Virus-Infected Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1932 - 1937. [Abstract] [Full Text]

				A. Strawford, T. Barbieri, M. Van Loan, E. Parks, D. Catlin, N. Barton, R. Neese, M. Christiansen, J. King, and M. K. Hellerstein Resistance Exercise and Supraphysiologic Androgen Therapy in Eugonadal Men With HIV-Related Weight Loss: A Randomized Controlled Trial JAMA, April 14, 1999; 281(14): 1282 - 1290. [Abstract] [Full Text] [PDF]

				C. Agostoni, G. V. Zuccotti, E. Riva, S. Decarlis, L. Bernardo, M. G Bruzzese, and M. Giovannini Low Levels of Linoleic Acid in Plasma Total Lipids of HIV-1 Seropositive Children J. Am. Coll. Nutr., February 1, 1998; 17(1): 25 - 29. [Abstract] [Full Text] [PDF]

				R. Chiolero, P. Schneiter, C. Cayeux, E. Temler, E. Jequier, C. Schindler, and L. Tappy Metabolic and Respiratory Effects of Sodium Lactate During Short IV Nutrition in Critically III Patients JPEN J Parenter Enteral Nutr, July 1, 1996; 20(4): 257 - 263. [Abstract] [PDF]

				S. Klein and J. Miles Substrate Metabolism in Humans: 1995 A.S.P.E.N. Research Workshop JPEN J Parenter Enteral Nutr, January 1, 1996; 20(1): 13 - 19. [Abstract] [PDF]

				S. J. Bell, S. Chavali, B. R. Bistrian, C. A. Connolly, T. Utsunomiya, and R. A. Forse Dietary Fish Oil and Cytokine and Eicosanoid Production During Human Immunodeficiency Virus Infection JPEN J Parenter Enteral Nutr, January 1, 1996; 20(1): 43 - 49. [Abstract] [PDF]